- Home
- BSET vs AARD Comparison
BSET vs AARD Comparison
Compare BSET & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BSET | AARD |
|---|---|---|
| Founded | 1902 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.9M | 107.7M |
| IPO Year | 1995 | 2025 |
Fundamental Metrics
Financial Performance| Metric | BSET | AARD |
|---|---|---|
| Price | $17.23 | $5.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $15.29 |
| AVG Volume (30 Days) | 15.0K | ★ 131.4K |
| Earning Date | 04-01-2026 | 05-14-2026 |
| Dividend Yield | ★ 5.49% | N/A |
| EPS Growth | ★ 163.06 | 43.11 |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $456,855,000.00 | N/A |
| Revenue This Year | $1.72 | N/A |
| Revenue Next Year | $3.78 | N/A |
| P/E Ratio | $46.73 | ★ N/A |
| Revenue Growth | ★ 0.96 | N/A |
| 52 Week Low | $13.17 | $3.35 |
| 52 Week High | $22.26 | $17.94 |
Technical Indicators
Market Signals| Indicator | BSET | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 30.93 | 40.34 |
| Support Level | $13.90 | $4.99 |
| Resistance Level | $17.53 | $6.01 |
| Average True Range (ATR) | 0.56 | 0.67 |
| MACD | -0.14 | -0.11 |
| Stochastic Oscillator | 8.16 | 17.39 |
Price Performance
Historical ComparisonAbout BSET Bassett Furniture Industries Incorporated
Bassett Furniture Industries Inc is a manufacturer, marketer, and retailer of home furnishings products in the United States. It operates through the following segments: The Wholesale segment focuses on the design, manufacture, sourcing, sale, and distribution of furniture products, the Retail segment which consists of company-owned stores, and the Corporate and others segment. Majority of revenue is from Wholesale sales of furniture and accessories.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.